Hematology

Top Story

Alprolix shows promise in treatment of severe pediatric hemophilia B

March 23, 2017

Recombinant Factor IX Fc fusion protein appeared safe and effective in the prevention and treatment of bleeding events in children with severe hemophilia B, according to results from the multicenter, open-label, phase 3 Kids B-LONG trial.

Recombinant Factor IX Fc fusion protein (Alprolix; Biogen, Sobi) is a recombinant clotting factor therapy developed for hemophilia B using Fc fusion technology to prolong circulation in the body. Factor IX is fused to the Fc portion of immunoglobin G subclass 1 to extend the therapy’s half-life.

Commentary

‘Cautiously reassuring’ picture emerges regarding sickle cell trait health risks

HemOnc Today, March 25, 2017
D. Alan Nelson, MPAS, PhD; Lianne M. Kurina, PhD
Liem and colleagues report that sickle cell trait is not associated with objectively measured fitness levels or cardiovascular disease risk factors. Utilizing data from…
Meeting News

Sickle cell anemia affects glomerular filtration rate, hyperfiltration

March 20, 2017
SAN DIEGO — Patients with sickle cell anemia experience a faster decline in the glomerular filtration rate and an increased prevalence of hyperfiltration among…
Meeting NewsPerspective

EINSTEIN-CHOICE: Recurrent VTE lower with rivaroxaban vs. aspirin, without rise in bleeding

March 18, 2017
WASHINGTON — Patients with venous thromboembolism assigned 10 mg or 20 mg of rivaroxaban had lower risk for recurrence compared with those who used aspirin, with…
CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »
Video
Meeting News Coverage

VIDEO: Physicians should recognize predictors of bleeding in hospitalized patients with cancer

December 30, 2016
More »
Featured
HEMONC TODAY Melanoma and Cutaneous Malignancies

HEMONC TODAY Melanoma and Cutaneous Malignancies

CME CNE CPE

Individualized Prophylaxis in Hemophilia

Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals

This program will provide education for hematologists, nurses, pharmacists, and other healthcare providers involved in…
More »
In the Journals Plus

Alprolix shows promise in treatment of severe pediatric hemophilia B

March 23, 2017
Recombinant Factor IX Fc fusion protein appeared safe and effective in the prevention and treatment of bleeding events in children with severe…

Commentary

‘Cautiously reassuring’ picture emerges regarding sickle cell trait health risks

HemOnc Today, March 25, 2017
D. Alan Nelson, MPAS, PhD; Lianne M. Kurina, PhD
Liem and colleagues report that sickle cell trait is not associated with objectively measured fitness levels or cardiovascular disease risk factors…

In the Journals PlusAbstract Only

Predicting Risk Of Venous Thromboembolism In Hospitalized Cancer Patients: Utility of A Risk Assessment Tool

March 20, 2017
AUTHORS:
Patell R, et al.

Meeting News

Sickle cell anemia affects glomerular filtration rate, hyperfiltration

March 20, 2017
SAN DIEGO — Patients with sickle cell anemia experience a faster decline in the glomerular filtration rate and an increased prevalence of…

Meeting NewsPerspective

EINSTEIN-CHOICE: Recurrent VTE lower with rivaroxaban vs. aspirin, without rise in bleeding

March 18, 2017
WASHINGTON — Patients with venous thromboembolism assigned 10 mg or 20 mg of rivaroxaban had lower risk for recurrence compared with those who…

Meeting News

Ruxolitinib may provide alternative treatment for patients with transfusion-dependent thalassemia

March 17, 2017
SAN DIEGO — Ruxolitinib demonstrated an improvement in transfused red blood cell volume during a 24-week treatment period compared with…

In the Journals

Sickle cell gene linked to increased risk for end-stage renal disease

March 17, 2017
Patients who carry the sickle cell trait were linked to a twofold increase in developing end-stage renal disease as opposed to noncarriers, according…

In the Journals

Anticoagulation often inadequate in patients with AF, ischemic stroke

March 14, 2017
Inadequate anticoagulation occurred often in patients with atrial fibrillation who had an acute ischemic stroke, according to a retrospective…

In the Journals Plus

Anemia during pregnancy increases risk for severe postpartum anemia

March 7, 2017
Women who have anemia while pregnant and experience postpartum hemorrhage following Cesarean section deliveries have a greater risk for severe…

In the Journals Plus

Gene therapy product shows early promise in sickle cell disease

March 2, 2017
A 13-year-old boy with sickle cell disease showed no signs of the disease and resumed normal activities 15 months after an infusion of LentiGlobin…

More Headlines »
Advertisement
Advertisement